Phenylbutazone-induced sialadenitis.
D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009055:Mouth / Q000473:pathology; D009061:Mouth Mucosa / Q000473:pathology; D009343:Neisseria / Q000302:isolation & purification; D010306:Parotid Gland / Q000378:metabolism; D010653:Phenylbutazone / Q000009:adverse effects*; D011193:Potassium Iodide / Q000627:therapeutic use; D012463:Saliva / Q000382:microbiology; D012466:Salivary Gland Diseases / Q000139:chemically induced*; D012588:Scintillation Counting; D012793:Sialadenitis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D012796:Sialography; D013291:Streptococcus / Q000302:isolation & purification; D014059:Tongue / Q000473:pathology
D011193:Potassium Iodide; D004917:Erythromycin; D010653:Phenylbutazone